Drugs / LANCASTOTUG
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05021120 | Oct 2021 → Oct 2024 | — | Akeso Biopharma, Inc. | Completed | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT05868876 | Jun 2023 → Nov 2025 overdue | cancer | Akeso | Recruiting | No outcome recorded |
| Phase 1 | NCT05393063 | Jun 2022 → Jun 2023 | cancer | Akeso | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06530251 | Sep 2024 → Jun 2026 overdue | hepatocellular carcinoma | Akeso | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05951608 | Oct 2023 → May 2026 overdue | cancer | Akeso | Active not recruiting | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-07-27 | Akeso | 康方卡度尼利联合TIGIT单抗（AK127）治疗晚期恶性肿瘤I期临床完成中国首例入组 akesobio.com ↗ |
| 2021-10-22 | Akeso | 康方生物开坦尼（PD-1/CTLA-4双抗）联合TIGIT单抗（AK127）治疗实体瘤临床试验在澳洲完成首例患者给药 akesobio.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LANCASTOTUG | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314843 ↗ |
| Known as | AK127 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06530251 ↗ |
| Action | Inhibit | “It can bind to human immune cells TIGIT with high affinity and competitively block the binding of TIGIT to its ligands CD155 and CD112.” NCT05868876 ↗ |
| Modality | Monoclonal antibody | “AK127 is a TIGIt-targeting IgG1 monoclonal antibody with complete Fc function.” NCT05868876 ↗ |
| Route | Intravenous | “by intravenous administration” NCT05021120 ↗ |
| Target | TIGIT | “AK127 is a TIGIt-targeting IgG1 monoclonal antibody with complete Fc function.” NCT05868876 ↗ |